Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.54 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27831975 | 0.99 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPK1CTSBHCRTR1HCRTR2 | |
| SCHEMBL2781032 | 0.90 | SMN1; SMN2 (0.55) | SMN1; SMN2MAPK1HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL20496747 | 0.87 | MAPK1 (0.55) | SMN1; SMN2MAPK1HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL21639569 | 0.86 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPK1HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL20496749 | 0.86 | ALDH1A1 (0.64) | SMN1; SMN2MAPK1HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL4906777 | 0.86 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPK1HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL4819066 | 0.85 | CTSB (0.60) | SMN1; SMN2CTSBALDH1A1KDM4EGAA | |
| SCHEMBL1421316 | 0.83 | CTSB (0.59) | CTSBALDH1A1KDM4EGAAPKM | |
| SCHEMBL21044059 | 0.83 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1KDM4EALOX15HSD17B10 | |
| SCHEMBL221971 | 0.83 | SMN1; SMN2 (0.56) | SMN1; SMN2MAPK1HCRTR1HCRTR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2778156-B1 | Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states | ASTRAZENECA AB (SE) | 2016-11-30 | — | — | EP | disclosed |
| EP-2778156-A1 | Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states | AstraZeneca AB (Publ) (SE) | 2014-09-17 | — | — | EP | disclosed |
| US-8273774-B2 | Phenoxypyridinylamide compounds | ASTRAZENECA AB (SE) | 2012-09-25 | — | — | US | disclosed |
| EP-2297106-A1 | PHENOXYPYRIDINYLAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PDE4 MEDIATED DISEASE STATES | AstraZeneca AB (SE) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010118968-A1 | NO-DONOR ASPIRIN DERIVATIVES | NICOX S.A. (FR) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010118968-A1 | NO-DONOR ASPIRIN DERIVATIVES | NICOX S.A. (FR) | 2010-10-21 | — | — | WO | disclosed |
| US-20100041638-A1 | Chemical Compounds 293 | ASTRAZENECA AB (SE) | 2010-02-18 | — | — | US | disclosed |
| WO-2009144494-A1 | PHENOXYPYRIDINYLAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PDE4 MEDIATED DISEASE STATES | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | WO | disclosed |
| US-20090239860-A1 | NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1710233-A1 | NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239860-A1 | NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE | ADORA2A, ADORA2B, HTR1F | SMN1; SMN2 2063/4885MAPK1 3982/4885CTSB 3340/4885 |
| US-20100041638-A1 | Chemical Compounds 293 | PDE4B, PDE4A, PDE3B | SMN1; SMN2 1711/4885MAPK1 1101/4885CTSB 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.